Group B Streptococcus Infection Treatment Global Market Report 2026

Description

Group B streptococcus infection treatment refers to the medical management of infections caused by Streptococcus agalactiae, affecting newborns, pregnant women, and immunocompromised adults. Treatment generally involves antibiotics to reduce bacterial load and prevent complications. Its main goal is to eliminate GBS bacteria, prevent adverse outcomes, and lower transmission risk, particularly from mother to infant.

The principal treatment types for Group B Streptococcus infection include antibiotic therapy, intravenous immunoglobulin, and experimental therapies. Antibiotic therapy involves using medications to eliminate or control bacterial infections caused by Group B Streptococcus. These treatments fall under drug classes such as beta-lactam antibiotics, clindamycin and alternatives, and pipeline therapies. Routes of administration include oral, intravenous, and topical applications. Patient types include newborns, pregnant women, immunocompromised individuals, and the elderly, with end users being hospitals, clinics, research institutions, and home care providers.

Tariffs are impacting the group B streptococcus infection treatment market by increasing costs of imported diagnostic kits, molecular testing reagents, pharmaceutical ingredients, and medical laboratory equipment. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported reagents and testing platforms, while Asia-Pacific faces higher costs in manufacturing and distribution of diagnostics. These tariffs are increasing treatment and screening costs and affecting procurement budgets. However, they are also encouraging domestic production of diagnostic kits, localized pharmaceutical manufacturing, and investment in regional healthcare supply chains to improve long-term availability.

The group b streptococcus infection treatment market research report is one of a series of new reports from The Business Research Company that provides group b streptococcus infection treatment market statistics, including group b streptococcus infection treatment industry global market size, regional shares, competitors with a group b streptococcus infection treatment market share, detailed group b streptococcus infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the group b streptococcus infection treatment industry. This group b streptococcus infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The group b streptococcus infection treatment market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing awareness of neonatal infections, expansion of prenatal care programs, widespread use of beta-lactam antibiotics, growth in hospital-based screening protocols, availability of microbiological testing services.

The group b streptococcus infection treatment market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing development of gbs vaccines, rising adoption of point-of-care diagnostics, growing focus on antimicrobial resistance management, expansion of molecular testing infrastructure, increasing emphasis on preventive maternal healthcare. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic testing, rising focus on prenatal gbs screening programs, growing use of antibiotic stewardship protocols, expansion of pipeline therapies for gbs prevention, enhanced monitoring of maternal and neonatal outcomes.

The rising healthcare expenditure is expected to propel the growth of the group B streptococcus infection treatment market going forward. Healthcare expenditure refers to the total financial resources allocated to medical services, preventive care, medications, infrastructure, and related health activities aimed at maintaining or improving population health. Healthcare expenditure is increasing due to the growing prevalence of chronic and infectious diseases, which fuels demand for long-term care, advanced therapies, and continuous medical management. Rising healthcare expenditure supports group B Streptococcus infection treatment by enabling greater investment in prenatal screening, clinical infrastructure, and vaccine research, thereby improving early detection, prevention, and effective management of GBS infections in mothers and newborns. For instance, in April 2025, according to the Office for National Statistics, a UK-based government organization, overall healthcare spending increased by 6.5% from 2023 to 2024, up from a 6.3% growth recorded in 2023. Therefore, the rising healthcare expenditure is driving the growth of the group B streptococcus infection treatment market.

Companies operating in the group B streptococcus infection treatment market are focusing on developing innovative products, such as polysaccharide conjugate vaccines, to reduce asymptomatic bacterial carriage. Polysaccharide conjugate vaccines are immunizations in which bacterial surface sugars are chemically linked to a carrier protein to enhance immune recognition and generate a strong, long-lasting protective response, especially in infants and young children. For example, in September 2023, Omniose, a US-based biotechnology company, announced a grant award of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine's unique feature lies in its aim to achieve high efficacy through a highly simplified manufacturing approach. Omniose's platform leverages synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, eliminating conventional chemical conjugation steps. This process preserves 100% of sialic acid residues on each capsular polysaccharide, a factor shown to be critical for inducing strong functional antibody responses against specific GBS serotypes.

In September 2024, MinervaX ApS, a Denmark-based biotechnology company developing a novel prophylactic vaccine against Group B Streptococcus (GBS), partnered with Wacker Biotech B.V. to scale up the manufacturing of active protein ingredients for MinervaX's GBS vaccine. Through this collaboration, MinervaX and Wacker Biotech aim to ensure robust late-stage clinical and commercial supply, enabling maternal vaccination to prevent adverse pregnancy outcomes and life-threatening infections in infants, as well as vaccination of older or at-risk adults. Wacker Biotech B.V. is a Germany-based company specializing in E. coli processes, technology transfer, process validation, and process characterization to support stable, high-quality vaccine production for global patient populations.

Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.

North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the group b streptococcus infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the group b streptococcus infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The group B streptococcus infection treatment market consists of revenues earned by entities by providing services such as prenatal screening and diagnostic testing, microbiological culture and molecular testing, clinical consultations for infection management, and antibiotic administration and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The group B streptococcus infection treatment market also includes sales of intrapartum prophylactic formulations, rapid diagnostic kits, molecular testing assays, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Group B Streptococcus Infection Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses group b streptococcus infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for group b streptococcus infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The group b streptococcus infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies
2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies
3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application
4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population
5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings
Subsegments:
1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics
2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy
3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies
Companies Mentioned: Merck & Co. Inc.; Pfizer Inc.; Sanofi S.A.; Novartis AG; GlaxoSmithKline plc; Biological E. Limited; Serum Institute of India Pvt. Ltd.; Walvax Biotechnology Co. Ltd.; Vaxcyte Inc.; Bharat Biotech International Limited; Clover Biopharmaceuticals Ltd.; Biovac Institute (Pty) Ltd.; Inventprise Inc.; BioNet Asia Co. Ltd.; GeneOne Life Science Inc.; Alopexx Enterprises LLC; Wellstat Vaccines LLC; MinervaX ApS; and ShanghAI Zerun Biotechnology Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MGBSI01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Group B Streptococcus Infection Treatment Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Group B Streptococcus Infection Treatment Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Group B Streptococcus Infection Treatment Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Group B Streptococcus Infection Treatment Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Artificial Intelligence & Autonomous Intelligence
- 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
4.2. Major Trends
- 4.2.1 Increasing Adoption Of Rapid Molecular Diagnostic Testing
- 4.2.2 Rising Focus On Prenatal Gbs Screening Programs
- 4.2.3 Growing Use Of Antibiotic Stewardship Protocols
- 4.2.4 Expansion Of Pipeline Therapies For Gbs Prevention
- 4.2.5 Enhanced Monitoring Of Maternal And Neonatal Outcomes

5. Group B Streptococcus Infection Treatment Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Clinics
5.3 Diagnostic Laboratories
5.4 Maternity Care Centers
5.5 Research Institutions

6. Group B Streptococcus Infection Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Group B Streptococcus Infection Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Group B Streptococcus Infection Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Group B Streptococcus Infection Treatment Market Size, Comparisons And Growth Rate Analysis
7.3. Global Group B Streptococcus Infection Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Group B Streptococcus Infection Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Group B Streptococcus Infection Treatment Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Group B Streptococcus Infection Treatment Market Segmentation

9.1. Global Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antibiotic Therapy, Intravenous Immunoglobulin (IVIG), Experimental Therapies
9.2. Global Group B Streptococcus Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Beta-Lactam Antibiotic, Clindamycin And Alternatives, Pipeline Therapies
9.3. Global Group B Streptococcus Infection Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral Administration, Intravenous Administration, Topical Application
9.4. Global Group B Streptococcus Infection Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Newborns, Pregnant Women, Immunocompromised Patients, Elderly Population
9.5. Global Group B Streptococcus Infection Treatment Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Clinics, Research Institutions, Home Care Settings
9.6. Global Group B Streptococcus Infection Treatment Market, Sub-Segmentation Of Antibiotic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Penicillin Based Antibiotics, Cephalosporin Antibiotics, Macrolide Antibiotics, Aminoglycoside Antibiotics
9.7. Global Group B Streptococcus Infection Treatment Market, Sub-Segmentation Of Intravenous Immunoglobulin (IVIG), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Standard Polyclonal Immunoglobulin, High Dose Immunoglobulin Therapy, Adjunctive Immunoglobulin Therapy
9.8. Global Group B Streptococcus Infection Treatment Market, Sub-Segmentation Of Experimental Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Vaccine Based Therapies, Monoclonal Antibody Therapies, Bacteriophage Therapies, Immunomodulatory Therapies

10. Group B Streptococcus Infection Treatment Market Regional And Country Analysis

10.1. Global Group B Streptococcus Infection Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Group B Streptococcus Infection Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Group B Streptococcus Infection Treatment Market

11.1. Asia-Pacific Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Group B Streptococcus Infection Treatment Market

12.1. China Group B Streptococcus Infection Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Group B Streptococcus Infection Treatment Market

13.1. India Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Group B Streptococcus Infection Treatment Market

14.1. Japan Group B Streptococcus Infection Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Group B Streptococcus Infection Treatment Market

15.1. Australia Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Group B Streptococcus Infection Treatment Market

16.1. Indonesia Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Group B Streptococcus Infection Treatment Market

17.1. South Korea Group B Streptococcus Infection Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Group B Streptococcus Infection Treatment Market

18.1. Taiwan Group B Streptococcus Infection Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Group B Streptococcus Infection Treatment Market

19.1. South East Asia Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Group B Streptococcus Infection Treatment Market

20.1. Western Europe Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Group B Streptococcus Infection Treatment Market

21.1. UK Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Group B Streptococcus Infection Treatment Market

22.1. Germany Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Group B Streptococcus Infection Treatment Market

23.1. France Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Group B Streptococcus Infection Treatment Market

24.1. Italy Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Group B Streptococcus Infection Treatment Market

25.1. Spain Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Group B Streptococcus Infection Treatment Market

26.1. Eastern Europe Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Group B Streptococcus Infection Treatment Market

27.1. Russia Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Group B Streptococcus Infection Treatment Market

28.1. North America Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Group B Streptococcus Infection Treatment Market

29.1. USA Group B Streptococcus Infection Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Group B Streptococcus Infection Treatment Market

30.1. Canada Group B Streptococcus Infection Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Group B Streptococcus Infection Treatment Market

31.1. South America Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Group B Streptococcus Infection Treatment Market

32.1. Brazil Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Group B Streptococcus Infection Treatment Market

33.1. Middle East Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Group B Streptococcus Infection Treatment Market

34.1. Africa Group B Streptococcus Infection Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Group B Streptococcus Infection Treatment Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Group B Streptococcus Infection Treatment Market Regulatory and Investment Landscape

36. Group B Streptococcus Infection Treatment Market Competitive Landscape And Company Profiles

36.1. Group B Streptococcus Infection Treatment Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Group B Streptococcus Infection Treatment Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Group B Streptococcus Infection Treatment Market Company Profiles
- 36.3.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. Group B Streptococcus Infection Treatment Market Other Major And Innovative Companies

Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, Shanghai Zerun Biotechnology Co. Ltd.

38. Global Group B Streptococcus Infection Treatment Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Group B Streptococcus Infection Treatment Market

41. Group B Streptococcus Infection Treatment Market High Potential Countries, Segments and Strategies

41.1 Group B Streptococcus Infection Treatment Market In 2030 - Countries Offering Most New Opportunities
41.2 Group B Streptococcus Infection Treatment Market In 2030 - Segments Offering Most New Opportunities
41.3 Group B Streptococcus Infection Treatment Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer